Major molecular response induced by nilotinib as first line treatment in a LMC patient with intermediate Sokal risk

Ursula Sessa, Maria Celentano, Stefano Rocco, Rossella Fabbricini, Olimpia Finizio, Vincenzo Mettivier



Here we describe a case of a man with chronic myeloid leukemia at intermediate risk, according to the Sokal index. After cytoreduction with hydroxyurea, the patient started nilotinib at standard dose (600 mg/day) obtaining a complete haematological response after one month of treatment.After about 3 months the patient presented a complete cytogenetic response and after six months major molecular response (MR3). At nine months of treatment the patient presented a complete molecular response (MR4).


Chronic myeloid leukemia; Optimal response; Nilotinib

Full Text



Abstract: 408 views
PDF: 313 views


  • There are currently no refbacks.